| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1201-9712(03)90037-3 |
| P698 | PubMed publication ID | 12718805 |
| P50 | author | John R Perfect | Q64932411 |
| William J Steinbach | Q89583459 | ||
| P2860 | cites work | Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P | Q24535844 |
| Multidrug-resistant Trichosporon asahii infection of nongranulocytopenic patients in three intensive care units | Q24550785 | ||
| Taxonomy, biology, and clinical aspects of Fusarium species | Q24615764 | ||
| Infection due to the fungus Acremonium (cephalosporium) | Q28250213 | ||
| In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole | Q28343353 | ||
| In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi | Q28343817 | ||
| In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens | Q28343832 | ||
| In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi | Q28355507 | ||
| In vitro activities of four novel triazoles against Scedosporium spp | Q28366842 | ||
| Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts | Q28368930 | ||
| In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi | Q28370628 | ||
| Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans | Q28379123 | ||
| Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis | Q28379219 | ||
| Penicillium marneffei: types and drug susceptibility. | Q30328124 | ||
| New and emerging yeast pathogens | Q30452880 | ||
| In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens. | Q31758369 | ||
| Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature | Q33540545 | ||
| Use of voriconazole in treatment of Scedosporium apiospermum infection: case report | Q33667583 | ||
| Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America | Q33894467 | ||
| In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents | Q33959506 | ||
| Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. | Q33968840 | ||
| Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi | Q33971884 | ||
| Treatment of murine fusariosis with SCH 56592 | Q33976439 | ||
| High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. | Q33976637 | ||
| In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans | Q33978865 | ||
| In vitro comparison of terbinafine and itraconazole against Penicillium marneffei | Q33979585 | ||
| Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis | Q34052582 | ||
| Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy | Q34092362 | ||
| Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections | Q34100318 | ||
| In vitro antifungal susceptibilities of Trichosporon species. | Q34106411 | ||
| Emerging pathogens | Q34154540 | ||
| Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century | Q34294875 | ||
| Transient fungemia due to Rhodotorula rubra in a cancer patient: case report and review of the literature | Q34300452 | ||
| Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases | Q34398225 | ||
| Infection due to Paecilomyces lilacinus: a challenging clinical identification | Q34452563 | ||
| Candida lusitaniae catheter-related sepsis | Q34495738 | ||
| Disseminated phaeohyphomycosis: review of an emerging mycosis | Q34498615 | ||
| Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii | Q35115472 | ||
| In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. | Q35135265 | ||
| In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates | Q35136251 | ||
| Treatment of murine Candida krusei or Candida glabrata infection with L-743,872 | Q35138062 | ||
| Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review | Q35535589 | ||
| Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine trichosporonosis | Q35822118 | ||
| Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals | Q36680382 | ||
| Disseminated zygomycosis: report of four cases and review | Q38717683 | ||
| In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates | Q39650951 | ||
| In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 | ||
| In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes | Q39651554 | ||
| Opportunistic zygomycotic infections. A literature review | Q39762217 | ||
| Paecilomyces lilacinus catheter-related fungemia in an immunocompromised pediatric patient | Q40187576 | ||
| Antifungal resistance in non- albicans Candida species | Q40691585 | ||
| Mucormycosis (zygomycosis): is there news for the clinician? | Q40698225 | ||
| Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission | Q41044976 | ||
| The new fungal opportunists are coming | Q41044994 | ||
| Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. | Q41582315 | ||
| Acremonium species: new emerging fungal opportunists--in vitro antifungal susceptibilities and review | Q41663895 | ||
| Trichosporon inkin peritonitis during continuous ambulatory peritoneal dialysis with bibliography review | Q41725277 | ||
| Trichosporon species infection in bone marrow transplanted patients. | Q43597716 | ||
| A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion | Q43670521 | ||
| In vitro antifungal activity of posaconazole against various pathogenic fungi | Q43715690 | ||
| Infection Caused byPenicillium marneffei: Description of First Natural Infection in Man | Q43811748 | ||
| Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate | Q44062197 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| Sepsis due to Rhodotorula related to use of indwelling central venous catheters | Q44932168 | ||
| Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis | Q45144771 | ||
| Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients | Q45756014 | ||
| In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens | Q49204090 | ||
| The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. | Q51192720 | ||
| Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. | Q51193284 | ||
| Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 | ||
| Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. | Q54033324 | ||
| Microbiological characteristics and susceptibility patterns of strains of Rhodotorula isolated from clinical samples. | Q54061836 | ||
| Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. | Q54091144 | ||
| Combination chemotherapy for the treatment of invasive infections by Scedosporium prolificans | Q58839976 | ||
| Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy | Q58840032 | ||
| Combined anti-fungal therapy and surgical resection as treatment of pulmonary zygomycosis in allogeneic bone marrow transplantation | Q59412910 | ||
| Disseminated trichosporonosis: Meeting the challenge | Q67884468 | ||
| Mucormycosis | Q68094584 | ||
| Fusarium solani infection during treatment for acute leukemia | Q69032177 | ||
| Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases | Q70020483 | ||
| Trichosporon inkin endocarditis: short-term evolution and clinical report | Q71616631 | ||
| Trends in the postmortem epidemiology of invasive fungal infections at a university hospital | Q71618317 | ||
| Successful treatment of a brain abscess due to Trichoderma longibrachiatum after surgical resection | Q71735242 | ||
| A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute | Q72741418 | ||
| In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole | Q73053427 | ||
| In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains | Q73153565 | ||
| Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group | Q73321118 | ||
| Zygomycosis in the 1990s in a tertiary-care cancer center | Q73893355 | ||
| Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology | Q74029269 | ||
| Acute invasive sinusitis due to Trichoderma longibrachiatum in a liver and small bowel transplant recipient | Q74314409 | ||
| The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis | Q74339631 | ||
| Torulopsis glabrata an emerging yeast pathogen in cancer patients | Q74601840 | ||
| In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin | Q77713217 | ||
| Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol | Q77931642 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 5-20 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | International Journal of Infectious Diseases | Q15262334 |
| P1476 | title | Newer antifungal therapy for emerging fungal pathogens | |
| P478 | volume | 7 |
| Q36111677 | Antifungal chemotherapeutics |
| Q35833407 | Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients |
| Q41009125 | Efficacy of micafungin in combination with other drugs in a murine model of disseminated trichosporonosis |
| Q53509592 | Mucormycosis mimicks sinusitis in a diabetic adult. |
| Q35587111 | New approaches to the risk of Candida in the intensive care unit |
| Q35790799 | Novel approaches to antifungal prophylaxis |
| Q48149245 | Omics for Investigating Chitosan as an Antifungal and Gene Modulator |
| Q35889819 | Prophylaxis and treatment of invasive candidiasis in the intensive care setting |
| Q35622016 | Scedosporium species infections and treatments |
| Q42722136 | Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation |
| Q42710747 | Synergistic antifungal activity of KB425796-C in combination with micafungin against Aspergillus fumigatus and its efficacy in murine infection models |
| Q39031540 | The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin |
| Q36491806 | Treatment of invasive infections due to rare or emerging yeasts and moulds |
Search more.